TP53 and malignant colon neoplasm: shown that the combination of oxaliplatin with the ellagitaninn metabolite urolithin A, modulates the proliferative potential of HCT116 colon cancer cells by p53-dependent mechanism, which results in the induction of p21 and TIGAR (TP53-Induced Glycolysis And Apoptosis Regulator) expression.